Novel treatment for intramedullary spinal cord tumors has been developed by a research team at the University of Illinois at Chicago. This therapy delivers chemotherapy drugs into the spinal cord to treat hard-to-reach spinal tumors using nanotechnology.
- A novel treatment for intramedullary spinal cord tumors has been developed.
- This treatment delivers chemotherapy drugs into the spinal cord to treat hard-to-reach spinal tumors using nanotechnology.
- Intramedullary spinal cord tumors are a type of central nervous system tumors that result in back or neck pain, radicular pain, gait disturbance, and bowel and bladder dysfunction.
Doxorubicin, a commonly used chemotherapy to treat spinal tumors, is delivered intravenously and affects the whole body with poor penetration to the spine. Radiation therapy is also problematic for these tumors because the radiation often damages healthy nearby spinal tissue and can have devastating effects, including paraplegia.
"Getting chemotherapy drugs to spinal tumors has always been a problem," said Dr. Ankit Mehta, assistant professor of neurosurgery and director of spinal oncology in the UIC College of Medicine and corresponding author on the paper. "But we can precisely guide chemotherapy to cancer cells into the spinal cord using magnetic nanoparticles."
The researchers used a unique rat model with implanted human intramedullary spinal cord tumors to show that magnetic nanoparticles could successfully be used to kill tumor cells.
First, they created nanoparticles made up of tiny, metallic magnets bound to particles of doxorubicin. Next, they implanted a magnet just under the skin covering the spinal vertebrae in the rat models. Then they injected the magnetic nanoparticles into the space around the spinal cord where the tumor was located.
"This proof-of-concept study shows that magnetic nanoparticles are an effective way to deliver chemotherapy to an area of the body that has been difficult to reach with available treatments," he said. "We will continue to investigate the potential of this therapy and hope to enter human trials if it continues to show promise."
- Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors - (https://www.nature.com/articles/s41598-018-29736-5)
Source-Eurekalert